Healthcare Business

biotech

NantKwest Enters the Market With a Bang

NantKwest (NASDAQ: NK) entered the market Tuesday with its initial public offering (IPO). The stock priced early Tuesday morning at $25 per share coming over the top of the expected ...
Read Full Story »
research

Was the Immunomedics Sell-Off Too Extreme?

Belgian pharmaceutical group UCB announced Tuesday morning that its phase 3 trial for lupus treatment epratuzumab failed to produce statistically significant results in both dosages tested in Systemic Lupus Erythematosus ...
Read Full Story »
pills

Are Merck Earnings Enough?

Merck & Co. Inc. (NYSE: MRK) reported its second-quarter financial results Tuesday before the markets opened. The pharmaceutical giant had $0.86 in earnings per share (EPS) on $9.8 billion in ...
Read Full Story »
Pills

Pfizer Overcomes Currency Exchange Issue with Stronger Sales of Cancer Drugs

Pfizer Inc. (NYSE: PFE) reported second quarter 2015 results before markets opened Tuesday morning. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.56 and revenues of $11.9 ...
Read Full Story »
biotech

Can Nymox Sustain This Massive Rally?

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) was one of the best performers on Monday despite a down day in the market. And Nymox is absolutely dominating in 2015 in terms of its ...
Read Full Story »
Pfizer logo

What to Look For in Pfizer Earnings

Before the market opens on Tuesday morning, Pfizer Inc. (NYSE: PFE) is scheduled to report second-quarter results. The company is expected to post earnings per share (EPS) of $0.52 on ...
Read Full Story »
Pills

What to Expect from Merck Earnings

Merck & Co. Inc. (NYSE: MRK) reports on Tuesday morning comes into earnings with shares up only 2.7% or so year to date, and up only about 1.7% from a ...
Read Full Story »
Biotechnology word cloud

Have Analysts Fully Priced in Praluent to Regeneron?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct ...
Read Full Story »
health care

Teladoc Shares Sell Off Despite Positive Initial Analyst Coverage

Teladoc Inc. (NYSE: TDOC) was a hot initial public offering this summer, and shares remain 50% higher than at the time of the IPO. The company sold some 8,250,000 shares ...
Read Full Story »
biotech

Aimmune Prepares For IPO By Setting Expected Price Range

Aimmune Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering. The expected price range was set as $14 to $16 for ...
Read Full Story »
Prescription drugs

Short Sellers Run For Cover From Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »

Teva Will Buy Allergan Generics for $40.5 Billion

In a deal which had been anticipated, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would buy Allergan Generics in a transaction valued at $40.5 billion. According to a press release ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
cemetery

Is This the End of Sunesis?

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) probably wishes that this Friday never happened. The company was already a very speculative cancer drug biotech outfit, and now its status is moving down ...
Read Full Story »